Cyanonilutamide

Cyanonilutamide (pronunciation: sy-an-oh-nil-uh-tam-ide) is a nonsteroidal antiandrogen (NSAA) that is used in the research for the treatment of prostate cancer. It is also known as ARN-509 and apalutamide.

Etymology

The term "Cyanonilutamide" is derived from the chemical structure of the compound. The prefix "cyano-" refers to the presence of a cyanide group in the molecule, while "nilutamide" is a reference to a similar antiandrogen drug, Nilutamide, from which Cyanonilutamide is derived.

Pharmacology

Cyanonilutamide acts as an antagonist of the androgen receptor, which is a type of nuclear receptor that is activated by binding of either of the androgenic hormones, testosterone, or dihydrotestosterone. By blocking the action of these hormones, Cyanonilutamide can slow the growth of prostate cancer cells.

Related Terms

Antiandrogen: A substance that inhibits the biological effects of androgen hormones.
Androgen receptor: A type of nuclear receptor that is activated by binding any of the androgenic hormones, usually testosterone and dihydrotestosterone.
Prostate cancer: A form of cancer that develops in the prostate, a gland in the male reproductive system.
Testosterone: The primary male sex hormone and an anabolic steroid.
Dihydrotestosterone: An endogenous androgen sex steroid and hormone.

External links

Medical encyclopedia article on Cyanonilutamide
Wikipedia's article - Cyanonilutamide

This WikiMD article is a stub. You can help make it a full article.

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Cyanonilutamide